secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001493152-22-008503
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace 2021 rev $41.3M (+28%), net loss improves to -$14.9M; CMS reversal on thyroid tests
--------------------------------------------------------------------------------

- Full year 2021 net revenue $41.3M, up 28% YoY; Q4 revenue $10.9M, up 13% YoY.
- Net loss improved to $(14.9)M from $(26.5)M; Adjusted EBITDA $(5.1)M vs $(15.4)M.
- Cash collections $43.1M, up 31%, outpacing revenue; DSO decreased 40% to 54 days.
- CMS retroactively reversed Jan 2022 billing policy for ThyGeNEXT/ThyraMIR; cash collections may be delayed.
- Appointed Dr. Vijay Aggarwal to board, replacing Eric B. Lev, effective Feb 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222008503/0001493152-22-008503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222008503/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-008503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer